CBD, Medicare, and the New FDA Enforcement Memo
We got a new FDA cannabis enforcement memo on Wednesday, April 1, regarding “hemp-derived CBD research in medical research models.” The general thrust.
We got a new FDA cannabis enforcement memo on Wednesday, April 1, regarding “hemp-derived CBD research in medical research models.” The general thrust.
Harris Sliwoski LLP attorney Jason Adelstone will be moderating a panel at the upcoming Industrial Hemp International Conference and Trade Show, in Denver,.
Sine die came for Oregon’s 2026 legislative session last Friday, March 6th. I previewed the roster of cannabis bills in play back on.
Most commentary on the “hemp ban” included in the November funding bill has focused on two related questions: (1) which products and activities.
In the last year or two, we have seen a growing number of marijuana businesses take the position that IRC 280E no longer.
Oregon’s 2026 legislative session began last week on February 2. The biennial “short session” will last but 35 days, and focus on budget.
Earlier this month, the Bailiwick of Jersey appeared poised to take a measured, evidence-based step toward re-examining its approach to non-medical cannabis. Three.
Last month, we hosted a webinar on federal cannabis law and policy in 2026. While things are not where we’d like them to.
Most commentary on the “hemp ban” included in the November funding bill has focused on two, related considerations: (1) which products and activities.
U.S. federal cannabis law is at a pivotal moment heading into 2026. In a January 15th webinar, attorneys Jason Adelstone and Vince Sliwoski.